Measuring relevant signals with the context each study requires
Together with you we define targeted assays and tailored panels to quantify biological processes, study response and strengthen translational interpretation.
The right panel for your question, your sample and your study
Talk to the team
We select biomarkers and combinations that connect the hypothesis with a quantifiable, traceable and interpretable measurement.
Targeted quantification helps test hypotheses on metabolism, inflammation, organ function and other processes linked to the phenomenon under study.
Longitudinal measurements make it possible to study baseline variation, change over time and differences in response between groups or profiles.
A coherent panel can help characterise subgroups, trajectories or degrees of involvement, without turning a single marker into a conclusion.
Targeted assays make it possible to evaluate candidates and signatures in new samples, always with controls, criteria and analyses matched to the validation objective.
The contexts shown illustrate possible applications. Each panel is defined by the objective, the matrix, the experimental design and analytical feasibility.
The strategy defines which signals we need to measure. The technology determines how to obtain them with the right sensitivity, range and controls. The right combination depends on the question, the matrix and the study design.
For studies with previously defined biomarkers, hypotheses or endpoints that require specific, traceable quantification.
For questions that need to combine complementary signals and obtain a more complete biological picture than a single analyte provides.
We work with different analytical technologies and select the most suitable one according to the analyte, the matrix, the expected range and the quality requirements of the study.
Targeted assays to quantify specific analytes (proteins, hormones, vitamins and other targets) in biomedical and translational research.
Reproducible measurement of selected biomarkers when the analyte, the range and the sample volume make this technology suitable.
Enzymatic, colorimetric and other targeted measurements to characterise metabolism and organ function.
Isolation of lipoprotein fractions and extracellular vesicles for their specific characterisation and quantification.
We organise the assays by biological context to make them easier to explore. The final selection starts from the question, not from a closed catalogue.
Targeted panels to study metabolic alterations, risk profiles and response in cohorts or interventions.
ApoB · ApoA-I · Lp(a) · Total cholesterol · HDL · LDL · Triglycerides · NEFAs
Glucose · HbA1c · Complementary markers depending on the study
ApoC3 · oxLDL · PCSK9
Isolation of lipoprotein fractions (VLDL/LDL/HDL) · Extracellular vesicles · ApoC3 quantified by fraction · Other quantifications by fraction depending on the study design
Proteins · Minerals · Selected biochemical variables
Assays selected to characterise the systemic response and its relationship with the phenotype or the intervention.
C-reactive protein · Calprotectin · Ferritin
IL-6 · MCP-1 · OSM · LIF
C3 · C4 · Other components depending on the question
Immunoglobulins · Specific proteins · Tailored panels
Targeted biochemistry to characterise mechanisms, safety, progression or response within the study design.
AST · ALT · GGT · Bilirubin
Creatinine · Urea · Uric acid
Total protein · Calcium · Magnesium
ELISA assays targeting processes that routine clinical biochemistry and inflammatory panels do not cover in detail.
ADAMTSL2 · FSTL1 · FABP3 · MSTN · GDF15
ACY1 · APLN · GS
Assays are confirmed after reviewing the objective, matrix, volume, expected range and quality requirements. We can assess other analytes and technically feasible combinations.
Biomarker catalogueExplore families, biological processes, matrices and measurement techniquesView the full catalogueWe work with immunoassay biomarkers, clinical biochemistry and fractionation of lipoproteins and extracellular vesicles. For assays outside this catalogue, such as genomic or mass spectrometry panels, we coordinate with specialised providers. Availability depends on the analyte, the matrix, the expected range, the volume and the study requirements.
Yes. We select biomarkers and methods based on the biological question, the available evidence, the experimental design and technical feasibility. Scope, controls and deliverables are agreed before the study starts.
Yes. A targeted measurement can complement a metabolic profile, help interpret mechanisms or be used to evaluate candidates identified in an exploratory phase.
It can support response monitoring, comparison between time points and exploratory endpoints when the panel, the sampling times and the analysis are properly defined in the protocol.
Yes. We can help select the technique, analyse new samples and combine the results. The validation strategy must be consistent with the intended use and the level of evidence required.
The volume depends on the technique and the number of assays per sample; we specify it when defining the panel. The timeline depends on the number of samples and the assays involved; we set it out in the proposal, together with the controls and deliverables.
Tell us the question, the available samples and the study design. We will propose the most suitable panel, technology and scope.
Send analytes and matrix
